19 public and industry partners across Europe are joining forces in an ambitious collaborative clinical research project with the aim of setting new standards for the clinical use of proton radiotherapy.
The public-private partnership named PROTECT-trial will conduct a large multi-institutional randomized control trial comparing the clinical outcome of proton therapy and state of the art photon radiotherapy for locally advanced esophageal cancer, with the goal of improving outcomes for this group of patients.
The partnership behind the PROTECT-trial engages 12 proton therapy centres, 17 academic partners, two leading industry partners and more than 30 clinical trial sites from eight countries. This project has received funding from the Innovative Medicines Initiative (IMI), EFPIA, IBA and Varian, a Siemens Healthineers company.
